Список литературы

1. Rajkumar S.V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma//The Lancet Oncology. Lancet Publishing Group, 2014. Vol. 15, N 12. P. e538 - e548.

2. Furukawa Y., Kikuchi J. Molecular pathogenesis of multiple myeloma.//Int. J. Clin. Oncol. 2015. Vol. 20, N 3. P. 413 - 422.

3. Lewis E.B. Leukemia, Multiple Myeloma, and Aplastic Anemia in American Radiologists//Science (80-.). 1963. Vol. 142, N 3598. P. 1492 - 1494.

4. Linet M.S., Harlow S.D., McLaughlin J.K. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use.//Cancer Res. 1987. Vol. 47, N 11. P. 2978 - 2981.

5. Hallek M., Bergsagel P.L., Anderson K.C. Multiple myeloma: increasing evidence for a multistep transformation process.//Blood. 1998. Vol. 91, N 1. P. 3 - 21.

6. Swerdlow S.H. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC)/ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.

7. Caers J. et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.//J. Hematol. Oncol. 2018. Vol. 11, N 1. P. 10.

8. Grammatico S., Scalzulli E., Petrucci M.T. Solitary Plasmacytoma//Mediterr J Hematol Infect Dis. 2017. Vol. 9, N 91. P. 1 - 14.

9. Guo S.Q. et al. Prognostic factors associated with solitary plasmacytoma//Onco. Targets. Ther. 2013. Vol. 6. P. 1659 - 1666.

10. Вотякова О.М., Менделеева Л.П. Солитарная плазмоцитома//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 302 - 307.

11. Wilder R.B. et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone//Cancer. 2002. Vol. 94, N 5. P. 1532 - 1537.

12. Thakar Y.S. et al. Immunochemical studies in multiple myeloma.//Indian J. Cancer. 1997. Vol. 34, N 4. P. 151 - 158.

13. Hill Q.A. et al. Outcome prediction in plasmacytoma of bone: A risk model utilizing bone marrow flow cytometry and light-chain analysis//Blood. American Society of Hematology, 2014. Vol. 124, N 8. P. 1296 - 1299.

14. Dingli D. et al. Immunoglobulin free light chains and solitary plasmacytoma of bone//Blood. 2006. Vol. 108, N 6. P. 1979 - 1983.

15. Менделеева Л.П., Вотякова О.М., Рехтина И.Г. Множественная миелома//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. Москва, 2018. P. 213 - 241.

16. Zamagni E. et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.//Haematologica. 2007. Vol. 92, N 1. P. 50 - 55.

17. Mendenhall W.M., Mendenhall C.M., Mendenhall N.P. Solitary plasmacytoma of bone and soft tissues.//Am. J. Otolaryngol. Vol. 24, N 6. P. 395 - 399.

18. Tsang R.W. et al. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group.//Int. J. Radiat. Oncol. Biol. Phys. 2018. Vol. 101, N 4. P. 794 - 808.

19. Tsang R.W. et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.//Int. J. Radiat. Oncol. Biol. Phys. 2001. Vol. 50, N 1. P. 113 - 120.

20. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

21. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group//Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.